Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.